Raymond James: 'The topline numbers presented by Black Diamond today indicate that the company has a viable asset in our view'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DGNX

Go back to Raymond James: 'The topline numbers presented by Black Diamond today indicate that the company has a viable asset in our view'

Stifel Defending Black Diamond Therapeutics (BDTX): 'we believe investors are underappreciating the breadth of mutation silevertinib is showing'

May 22, 2026 9:37 AM EDT

Stifel analyst Laura Prendergast reiterated a Buy rating and $8.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).

The analyst comments "We view the preliminary median PFS of 15.2 months as highly encouraging and perhaps practice changing - the DoR had not yet been reached. 44% of patients are progression free/still on drug with median follow up ~9.8 months, suggesting PFS could increase with longer follow up. What stands out to us the most is: The breadth of mutations seen in patients who are progression free for 1 year (10 unique mutations across 8 patients). The lack of any CNS... More

TD Cowen on Black Diamond Therapeutics (BDTX) Amid 18% Drop: 'is unclear if the FDA will require Ph3 run-in or additional Ph2 dosing work extending competitor's lead'

May 22, 2026 9:36 AM EDT

TD Cowen analyst Marc Frahm reiterated a Buy rating and {REMOVEPT} price target on Black Diamond Therapeutics (NASDAQ: BDTX).

The analyst comments "BDTX shared updated 1L data for 200mg silevertinib, including a preliminary mPFS of 15.2m, 60% ORR (86% CNS), and slightly increased dose-reduction... More

H.C. Wainwright Reiterates Buy Rating on Black Diamond Therapeutics (BDTX)

May 22, 2026 6:57 AM EDT

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $11.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).

The analyst commented: "Yesterday, Black Diamond presented updated Phase 2 results, including duration of response (DOR) and progression-free survival (PFS) results, for silevertinib (BDTX-1535) in 1L NSCLC patients harboring non-classical EGFR mutations. As seen in the company's presentation, silevertinib (n=43; 44% brain metastases; 74% Caucasian) achieved a 60% [26/43] confirmed objective response rate (cORR) and an 86% [6/7] intracranial cORR in NSCLC... More

Black Diamond reports phase 2 lung cancer trial results for silevertinib

May 21, 2026 5:14 PM EDT

Black Diamond Therapeutics Inc. (NASDAQ: BDTX) announced results from a Phase 2 trial of silevertinib in treatment-naïve non-small cell lung cancer patients with epidermal growth factor receptor non-classical mutations.



The trial enrolled 43 patients who received 200 mg once daily of silevertinib. Results showed a preliminary median progression-free... More